HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
Nature Genetics2014Vol. 46(10), pp. 1131–1134
Citations Over TimeTop 1% of 2014 papers
Graham Heap, IBD Pharmacogenetics Study Group, Michael N. Weedon, Claire Bewshea, Abhey Singh, Mian Chen, Jack Satchwell, J.P. Vivian, Kenji So, P Dubois, Jane M. Andrews, Vito Annese, Peter A. Bampton, Martin Barnardo, Sally Bell, Andy Cole, Susan J. Connor, Tom Creed, Fraser Cummings, Mauro D’Amato, Tawfique K. Daneshmend, Richard N. Fedorak, Timothy H. Florin, Daniel R. Gaya, Emma I. Greig, Jonas Halfvarson, Alisa Hart, Peter M. Irving, Gareth‐Rhys Jones, Amir Karban, Ian C. Lawrance, James Lee, Charlie W. Lees, Raffi Lev‐Tzion, James O. Lindsay, John Mansfield, Joel Mawdsley, Zia Mazhar, Miles Parkes, Kirstie Parnell, Timothy R. Orchard, Graham Radford‐Smith, Richard K. Russell, David Reffitt, Jack Satsangi, Mark S. Silverberg, G Sturniolo, Mark Tremelling, Epameinondas V. Tsianos, David A. van Heel, Alissa Walsh, Gill Watermeyer, Rinse K. Weersma, Sebastian Zeißig, Jamie Rossjohn, Arthur L. Holden, Tariq Ahmad
Related Papers
- → Mercaptopurine and inflammatory bowel disease: the other thiopurine(2016)7 cited
- → Thiopurine therapy: when to start and when to stop.(2003)18 cited
- → Thiopurine therapy(2003)10 cited
- Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease(2011)
- → Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine(2008)1 cited